[小细胞肺癌免疫检查点抑制剂中疗效生物标志物的现状与未来]
[Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors of Small Cell Lung Cancer].
作者信息
Yang Yaning, Wang Yan
机构信息
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2020 Oct 20;23(10):897-903. doi: 10.3779/j.issn.1009-3419.2020.101.42. Epub 2020 Aug 10.
Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer. However, the survival benefits emerged after three to six months since therapy initiation. A growing body of evidence suggested that the current biomarkers were not consistent and convincing. Here, we review the current biomarkers including PD-L1, tumor mutation burden, DNA damage response pathway. Furthermore, we elucidate the potential biomarkers, such as tumor-infiltrating lymphocytes, circulating tumor cells. .
免疫检查点的抑制，包括程序性细胞死亡蛋白1-程序性细胞死亡配体1（PD-1-PD-L1）轴、细胞毒性T淋巴细胞相关抗原4，处于小细胞肺癌免疫治疗的前沿。然而，生存获益在治疗开始后的三到六个月才显现出来。越来越多的证据表明，目前的生物标志物并不一致且缺乏说服力。在此，我们回顾了当前的生物标志物，包括PD-L1、肿瘤突变负荷、DNA损伤反应途径。此外，我们阐明了潜在的生物标志物，如肿瘤浸润淋巴细胞、循环肿瘤细胞。
Zotero 插件